NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02088515,Nedaplatin (JiebaishuÂ®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma,https://clinicaltrials.gov/study/NCT02088515,,COMPLETED,"The treatment of squamous cell carcinoma of lung has not improved suffuciently. Nedaplatin is a second-generation platinum compound that is more active against squamous cell carcinoma of the lung with a response rate of 60%, issued by the finished Phase II trial in Japan.",NO,Squamous Cell Carcinoma,DRUG: Nedaplatin|DRUG: Cisplatin|DRUG: Docetaxel,"progress free survival, after being enrolled, the subjects will be subject to 4 cycles chemotherapy (each cycle: 21 days). if complete response/partial response/stable desease is confirmed, the subjects will be followed up till to the sixth months., 9 months","Objective Response Rate, the effectiveness will be evaluated after 2 cycles of chemotherapy is finished. 4 cycles of chemotherapy is needed for each subject., 3 months","Adverse Events, Adverse Events will be recorded and monitored till to normal or basal level achieved., 10 months","Jiangsu Simcere Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE4,290,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,5501068,2013-12,2016-10,2017-02,2014-03-17,,2017-03-03,"Hunan Xiangya Hospital, Changsha, Hunan, China|Nanjing Military General Hospital, Nanjing, Jiangsu, China|Shanghai Chest hospital, Shanghai, Shanghai, 200000, China|Xijing Hospital, Xian, Shanxi, China",
